Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ABOS
- Price
- 1.99
- Stock movement up
- +0.12 (5.02%)
- Company name
- Acumen Pharmaceuticals Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 152.04M
- Ent value
- 154.26M
- Price/Sales
- 854.15
- Price/Book
- 1.63
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -
- 1 year return (CAGR)
- 83.21%
- 3 year return (CAGR)
- -25.00%
- 5 year return (CAGR)
- -
- 10 year return (CAGR)
- -
Last updated: 2026-02-13
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ABOS does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 854.15 |
| Price to Book | 1.63 |
| EV to Sales | 866.60 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 60.57M |
| EPS (TTM) | -2.20 |
| FCF per share (TTM) | -2.04 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 178.00K |
| Gross profit (TTM) | -89.00K |
| Operating income (TTM) | -138.23M |
| Net income (TTM) | -133.35M |
| EPS (TTM) | -2.20 |
| EPS (1y forward) | -1.94 |
Margins
Loading...
Margins data
| Gross margin (TTM) | -50.00% |
| Operating margin (TTM) | -77657.30% |
| Profit margin (TTM) | -74916.29% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 46.83M |
| Net receivables | 379.00K |
| Total current assets | 132.15M |
| Goodwill | 0.00 |
| Intangible assets | 30.00K |
| Property, plant and equipment | 288.00K |
| Total assets | 142.22M |
| Accounts payable | 682.00K |
| Short/Current long term debt | 30.84M |
| Total current liabilities | 21.96M |
| Total liabilities | 49.05M |
| Shareholder's equity | 93.17M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -123.66M |
| Capital expenditures (TTM) | 88.00K |
| Free cash flow (TTM) | -123.75M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -143.12% |
| Return on Assets | -93.76% |
| Return on Invested Capital | -107.57% |
| Cash Return on Invested Capital | -99.82% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 2.39 |
| Daily high | 2.65 |
| Daily low | 2.38 |
| Daily Volume | 282K |
| All-time high | 20.28 |
| 1y analyst estimate | 7.00 |
| Beta | 0.24 |
| EPS (TTM) | -2.20 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 30 Mar 2026 |
Downside potential
Loading...
Downside potential data
| ABOS | S&P500 | |
| Current price drop from All-time high | -90.19% | -0.89% |
| Highest price drop | -95.56% | -56.47% |
| Date of highest drop | 17 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -76.56% | -10.86% |
| Avg time to new high | 580 days | 12 days |
| Max time to new high | 1160 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
152.04M
Marketcap category
Small-cap
Description
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate Sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2, which has completed the INTERCEPT-AD phase 1 clinical trial and in ALTITUDE-AD phase 2 clinical trial to target soluble amyloid-beta oligomers. It has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Newton, Massachusetts.
Employees
61
Website
Investor relations
-
SEC filings
CEO
Country
USA
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page